CMMB
Chemomab Therapeutics Ltd.Company with tickers: CMMB
CIK
1534248
CUSIP
16385C203
Shares Outstanding
7,200,378
13F Activity (30d)
12 filings
12 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $4,393,000 | USD | 2023-12-31 | 20-F | 2026-03-23 |
| Gross Profit | — | ||||
| Operating Expenses | $25,459,000 | USD | 2023-12-31 | 20-F | 2026-03-23 |
| Research & Development | $18,381,000 | USD | 2023-12-31 | 20-F | 2026-03-23 |
| Operating Income | $-112,000,000 | USD | 2025-12-31 | 20-F | 2026-03-23 |
| Net Income | $-24,221,000 | USD | 2023-12-31 | 20-F | 2026-03-23 |
| EPS (Basic) | $0.10 | USD/shares | 2023-12-31 | 20-F | 2026-03-23 |
| EPS (Diluted) | $0.10 | USD/shares | 2023-12-31 | 20-F | 2026-03-23 |